What is pathophysiology of Lung cancer?

Wuliriza olupapula luno

Pathophysiology ya kookolo w'amawuggwe y'eruwa?

Pathophysiology ya kkansa y'amawuggwe eyogera ku nkyukakyuka mu nkola za physiological eza bulijjo n'enkola ezikolebwa mu kukulaakulana n'okukulaakulana kwa kkansa y'amawuggwe.

Obulwadde bwa kkansa w'amawuggwe bulwadde obw'amaanyi obuva ku kukula n'okwawula kw'obutoffaali obutali bwa bulijjo mu mawuggwe.

Obutoffaali buno busobola okukola obutoffaali ne busasaana mu bitundu ebirala eby'omubiri, ne buviirako obubonero n'ebizibu eby'enjawulo.

Enkola y'obulwadde bwa kkansa y'amawuggwe erimu ebintu ebiwerako, nga mw'otwalidde n'enkyukakyuka mu nsolo, embeera y'obutonde, n'engeri y'obulamu.

Enkyukakyuka z'ekika ziyinza okubaawo mu DNA y'obutoffaali bw'amawuggwe, ne biviirako obutoffaali okukula n'okugabanyizibwamu.

Enkyukakyuka zino ziyinza okusikira oba okuweebwa omuntu, era ziyinza okuva ku bintu ebireeta kookolo, gamba ng'omukka gw'emmwaanyi, radon, asbestos, n'empewo eyonoonese.

Obulwadde bwa kkansa w'amawuggwe busobola okwawulibwa mu ngeri bbiri enkulu: small cell lung cancer (SCLC) ne non-small cell lung cancer (NSCLC). NSCLC esobola okwawulibwa mu subtypes ssatu: adenocarcinoma, squamous cell carcinoma, ne large cell carcinoma.

Pathophysiology y'ebika bino ebya kkansa y'amawuggwe eyinza okwawukana, kubanga birina obuwuka obw'enjawulo era biddamu obujjanjabi mu ngeri ey'enjawulo.

Pathophysiology ya kkansa y'amawuggwe era erimu n'enkolagana wakati w'obutoffaali bwa kkansa n'ebiwundu ebiriraanyeewo, nga mw'otwalidde n'obutoffaali bw'omubiri.

Obutoffaali bw'akawuka busobola okwewala obukuumi bw'omubiri, ne busobozesa okukula n'okusaasaana awatali kuziyizibwa.

Okugatta ku ekyo, embeera y'omubiri ey'obulwadde bw'omusaayi esobola okutumbula okukula kw'omusaayi n'okusaasaana kw'omusaayi ng'ewa obuwagizi eri obutoffaali bw'omusaayi.

Pathophysiology ya kkansa y'amawuggwe nkola nzibu era ey'amaanyi, era abanoonyereza bakola buli kiseera okutegeera obulungi enkola eziri wansi w'ekirwadde kino okusobola okukulaakulanya obujjanjabi obusingako obulungi n'okulongoosa embeera y'abalwadde.

Ebikwata ku bantu

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.

Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.

Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.

Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .

Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .

Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.

Okwewala obuvunaanyizibwa: eby'obujjanjabi

Omukutu guno guweereddwa olw'ebigendererwa by'enjigiriza n'obubaka bwokka era teguwa kubuulirira kw'ekisawo oba obuweereza bw'ekikugu.

Obubaka obuweereddwa tebusaanidde kukozesebwa okuzuula oba okujjanjaba bulwadde, era abo abanoonya amagezi g'ekisawo balina okwebuuza ku musawo alina layisensi.

Weetegereze nti enkola ya neural net ekola eby'okuddamu mu bibuuzo, si ntuufu nnyo bwe kituuka ku muwendo gw'abantu. Ng'ekyokulabirako, omuwendo gw'abantu abalwadde obulwadde obumu.

Bulijjo noonya amagezi g'omusawo wo oba omusawo omulala omutuufu ku bikwata ku mbeera y'obulamu. Teweerabira magezi g'omusawo oba okulwawo okuganoonya olw'ekintu ky'osomye ku mukutu guno. Bw'oba olowooza oyinza okuba n'embeera ey'amangu mu by'obulamu, yita 911 oba genda mu ddwaaliro ly'amangu erisinga okumpi amangu ddala. Tewali nkolagana ya musawo n'omulwadde ekolebwa ku mukutu guno oba okukozesawo. BioMedLib oba abakozi baagwo, oba omuntu yenna ayamba ku mukutu guno, talina ky'agamba, ekyogamba oba ekiteeberezebwa, ku bikwata ku bubaka obuli wano oba okukozesawo.

Okwewala obuvunaanyizibwa: eddembe ly'okuwandiika

Digital Millennium Copyright Act ey'omwaka 1998, 17 U.S.C. § 512 (DMCA) ewa abalina eddembe ly'okuwandiika ebitabo abakkiriza nti ebintu ebiri ku mutimbagano bikontana n'eddembe lyabwe wansi w'amateeka g'eddembe ly'okuwandiika ebitabo mu Amerika.

Bw'oba olowooza mu bwesimbu nti ebintu oba ebintu ebikolebwa ku mukutu gwaffe ogwa webusayiti oba obuweereza bikontana n'amateeka go ag'eddembe ly'obuntu, ggwe (oba omubaka wo) osobola okututumira obubaka ng'osaba ebintu oba ebintu ebyo biggyibwe, oba okukugira.

Okumanyisa kulina okusindikibwa mu buwandiike nga bakozesa e-mail (laba ekitundu "Contact" ku adirisa ya e-mail) .

DMCA yeetaaga nti ekiwandiiko kyo eky'okuvumirira obutali bwenkanya bw'eddembe ly'obuntu kitwaliramu obubaka buno: (1) okunnyonnyola omulimu oguli wansi w'eddembe ly'obuntu ogugambibwa obutali bwenkanya; (2) okunnyonnyola ebintu ebigambibwa obutali bwenkanya n'obubaka obumala okutusobozesa okuzuula ebintu ebyo; (3) obubaka bw'okuwuliziganya naawe, nga mw'otwalidde endagiriro yo, ennamba ya ssimu n'ennamba ya e-mail; (4) ekiwandiiko okuva gy'oli ekiraga nti olina okukkiriza okutuufu nti ebintu mu ngeri ey'okwemulugunya tebikkirizibwa nnannyini ddembe ly'obuntu, oba omubaka we, oba mu nkola y'amateeka.

(5) ekiwandiiko ky'oyimirizza, wansi w'omusango gw'okubuusabuusa, nti obubaka obuli mu kiwandiiko kituufu era nti olina obuyinza okussa mu nkola eddembe ly'okuwandiika erigambibwa okuba nga lyamenyebwa;

era (6) omukono ogw'omubiri oba ogw'oku mutimbagano ogwa nnannyini copyright oba omuntu ow'obuyinza okukolera mu linnya lya nnannyini copyright.

Okulemererwa okuteeka obubaka bwonna obuli waggulu kuyinza okuleetawo obudde mu kutambuza okwemulugunya kwo.

Okuwuliziganya

Tukusaba otutumire e-mail n'ebibuuzo / amagezi.

What is pathophysiology of lung cancer?

The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.

Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.

These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.

The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.

Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.

These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.

Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.

The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.

Cancer cells can evade the immune system, allowing them to grow and spread unchecked.

Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.

The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.